Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Jefferies Financial Group dropped their Q3 2018 earnings estimates for Intercept Pharmaceuticals in a research report issued to clients and investors on Monday, October 8th. Jefferies Financial Group analyst M. Yee now expects that the biopharmaceutical company will post earnings of ($2.78) per share for the quarter, down from their prior estimate of ($2.69). Jefferies Financial Group also issued estimates for Intercept Pharmaceuticals’ Q4 2018 earnings at ($2.84) EPS, FY2018 earnings at ($11.37) EPS and FY2019 earnings at ($10.20) EPS.
ICPT has been the subject of a number of other research reports. Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, August 2nd. Wedbush restated a “buy” rating and set a $203.00 price objective (down previously from $217.00) on shares of Intercept Pharmaceuticals in a research report on Friday, August 3rd. BidaskClub lowered Intercept Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd. ValuEngine upgraded Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. Finally, Royal Bank of Canada reiterated a “buy” rating and set a $115.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, August 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company’s stock. Intercept Pharmaceuticals has an average rating of “Buy” and a consensus target price of $136.17.
NASDAQ:ICPT opened at $103.73 on Thursday. Intercept Pharmaceuticals has a 12-month low of $51.05 and a 12-month high of $133.74. The company has a market cap of $3.74 billion, a P/E ratio of -7.20 and a beta of -1.94. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 2.48.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($2.58) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.83) by $0.25. Intercept Pharmaceuticals had a negative return on equity of 614.15% and a negative net margin of 215.30%. The business had revenue of $43.58 million during the quarter, compared to analyst estimates of $41.26 million. During the same quarter in the previous year, the firm posted ($3.46) EPS. The business’s revenue for the quarter was up 41.1% compared to the same quarter last year.
A number of hedge funds have recently made changes to their positions in ICPT. US Bancorp DE raised its stake in shares of Intercept Pharmaceuticals by 821.6% in the 1st quarter. US Bancorp DE now owns 1,751 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,561 shares in the last quarter. Tocqueville Asset Management L.P. bought a new stake in shares of Intercept Pharmaceuticals in the 2nd quarter worth $252,000. Sheaff Brock Investment Advisors LLC bought a new stake in shares of Intercept Pharmaceuticals in the 2nd quarter worth $264,000. United Services Automobile Association bought a new stake in shares of Intercept Pharmaceuticals in the 2nd quarter worth $280,000. Finally, Xact Kapitalforvaltning AB bought a new stake in shares of Intercept Pharmaceuticals in the 2nd quarter worth $282,000. Institutional investors own 69.38% of the company’s stock.
In other Intercept Pharmaceuticals news, insider David Shapiro sold 4,917 shares of the business’s stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $111.43, for a total transaction of $547,901.31. Following the completion of the transaction, the insider now owns 42,196 shares in the company, valued at approximately $4,701,900.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.90% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Featured Article: Trading Strategy Methods for Individual Investors
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.